• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

by Elizabeth | Apr 28, 2025 | News

Pancreatic cyst abstracts build on endorsement of Cellvizio® by Europe’s leading endoscopy society, ESGE, as a key tool for improving pancreatic cyst diagnostic accuracy  AI, pancreatic cancer, and food intolerance once again headline wide range of Cellvizio®...
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

by Elizabeth | Apr 24, 2025 | News

 Commercial activities remain strong, including CellTolerance® launch  Recently approved safeguard proceeding yielding productive creditor and investor discussions aimed at strengthening Mauna Kea’s long-term financial position  Currently in exclusive...
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player 

by Elizabeth | Apr 1, 2025 | News

 The Company also confirms that it is pursuing licensing discussions in other therapeutic areas  The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify discussions on financing options with long-term investors ...
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies announces the opening of a safeguard proceeding to restructure its financial liabilities 

by Elizabeth | Mar 31, 2025 | News

 The aim of the procedure is to optimize the Company’s financial structure in order to adapt it to the needs of its future growth  The procedure will also provide a protective framework favorable to the progress of ongoing discussions with strategic...
Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis

Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis

by Elizabeth | Mar 3, 2025 | News

ESGE, Europe’s leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step towards broader commercial adoption  Paris and Boston, March 3, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 
  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}